-
-
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market.
-
Patients with painless acute aortic dissection are more likely to present with syncope, congestive heart failure or stroke, and have a higher mortality, especially with type B dissection.
-
Patients who use both erythromycin and CYP3A inhibitors, particularly calcium channel blockers, had an increased risk of sudden death from cardiac causes.
-
-
The FDA has approved a new drug for the management of alcohol dependence.
-
Studies on HCV infection resolution show that PBMC HCV-RNA may remain, despite clearance of the virus from plasma.
-
Headaches commonly attributed to sinus are very likely to be migraines.
-
-
A new and as yet unpublished study has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events.
